CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

State of the Art in Noninvasive Imaging of Ischemic Heart Disease and Coronary Microvascular Dysfunction in Women: Indications, Performance, and Limitations Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization Novel functions of macrophages in the heart: insights into electrical conduction, stress, and diastolic dysfunction Hs-cTroponins for the prediction of recurrent cardiovascular events in patients with established CHD - A comparative analysis from the KAROLA study Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents 2-Year Clinical Outcomes: From the BIONICS and NIREUS Trials Post-Stroke Cardiovascular Complications and Neurogenic Cardiac Injury: JACC State-of-the-Art Review Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?

Review ArticleVolume 70, Issue 17, October 2017, Pages 2171-2185

JOURNAL:J Am Coll Cardiol. Article Link

How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD

Hong KN, Fuster V, Bhatt DL et al. Keywords: cardiovascular disease; diabetes; hyperlipidemia; hypertension; primary prevention

ABSTRACT

Diabetes, hyperlipidemia, and hypertension are modifiable risk factors that predict cardiovascular disease events. The effect of these risk factors on incident cardiovascular disease increases with progressively higher levels of glucose, low-density lipoprotein cholesterol, and blood pressure. The thresholds for initiating treatment of these modifiable risk factors and the optimal goals of risk factor modification are a focus of primary prevention research. Although an aggressive approach is appealing, adverse events may occur, and potential physiological barriers may exist. This paper discusses primary prevention of coronary heart disease that may be achieved through modification of diabetes, hyperlipidemia, and hypertension by summarizing current guidelines and pertinent clinical trial data from intervention trials that included a primary prevention cohort.